Activation of Ecto-5’-nucleotidase Mediates Cardioprotection in Ischemic Preconditioning: Important Role of Protein Kinase C

  • Masafumi Kitakaze
  • Tetsuo Minamino
  • Koichi Node
  • Hiroharu Funaya
  • Masatsugu Hori
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 194)


When brief periods of ischemia precede sustained ischemia, infarct size is markedly limited, a phenomenon known as ischemic preconditioning.1’2 The precise mechanisms underlying this phenomenon have been investigated3’4 because identification of the primary mediator of ischemic preconditioning may contribute to the development of the potential treatment of acute myocardial infarction. Several lines of evidence suggest that beneficial effects of ischemic preconditioning are observed in the clinical settings.5’6 Recently, Liu et al7 experimentally demonstrated that an exposure to 8-sulfophenyltheophylline blunts the infarct size-limiting effect of ischemic preconditioning, and that brief periods of exposures to adenosine, instead of transient ischemia, mimic ischemic preconditioning. Thornton et al.8 showed that adenosine A1, receptors activation is responsible for the infarct size-limiting effect of ischemic preconditioning. Indeed, it has been clarified that adenosine contributes to limit infarct size.9’10 There are two different possibilities by which adenosine links with cardioprotection in ischemic preconditioning. One possibility is that release of adenosine during ischemia and reperfusion is enhanced by ischemic preconditioning, and the other possibility is that released adenosine makes myocardium resistant to ischemia and reperfusion. Here, we will discuss the possibility that ischemic preconditioning activates the enzymes responsible for adenosine release, i.e., ecto-5’-nucleotidase, and test the cause-effect relationship between activation of ecto-5’-nucleotidase and the infarct size-limiting effect in ischemic preconditioning.


Infarct Size Adenosine Receptor Ischemic Precondition Coronary Occlusion Nucleotidase Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124–1136.PubMedCrossRefGoogle Scholar
  2. 2.
    Li GC, Vasquez JA, Gallagher KP et al. Myocardial protection with preconditioning. Circulation 1990;82:609–619.PubMedCrossRefGoogle Scholar
  3. 3.
    Murry CE, Richard VJ, Reimer KA et al. Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode. Circ. Res. 1990;66:913–931.PubMedCrossRefGoogle Scholar
  4. 4.
    Steenbergen CM, Perlman R, London E et al. Mechanism of preconditioning Ionic alterations. Circ Res. 1993;72:112–125.PubMedCrossRefGoogle Scholar
  5. 5.
    Deutsch E, Berger M, Kussmaul WG et al. Adaptation in ischemia during percutaneous transmural coronary angioplasty. Clinical, hemodynamic, and metabolic features. Circulation 1990;82:2044–2051.PubMedCrossRefGoogle Scholar
  6. 6.
    Okazaki Y, Kodama K, Sato H et al. Attenuation of increased regional oxygen consumption during exercise as a major cause of warm-up phenomenon. J. Am. Coll. Cardiol. 1993;21:1597–1604.PubMedCrossRefGoogle Scholar
  7. 7.
    Liu GS, Thornton J, Van Winkle DM et al. Protection against infarction afforded by preconditioning is mediated by Al adenosine receptors in rabbit heart. Circulation 1991;84:350–356.PubMedCrossRefGoogle Scholar
  8. 8.
    Thornton JD, Liu GS, Olsson RA et al. Intravenous pretreatment with Al-selective adenosine analogue protects the heart against infarction. Circulation 1992;85:659–665.PubMedCrossRefGoogle Scholar
  9. 9.
    Miura T, Ogawa T, Iwamoto T et al. Dipyridamole potentiates the myocardial infarct size-limiting effect of ischemic preconditioning. Circulation 1992;86:979–985.PubMedCrossRefGoogle Scholar
  10. 10.
    Olafsson B, Forman MB, Puett DW et al. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon. Circulation 1987;76:1135–1145.PubMedCrossRefGoogle Scholar
  11. 11.
    Kitakaze M., Hori M, Takashima S et al. Ischemic preconditioning increases adenosine release and 5’-nucleotidase activity during myocardial ischemia and reperfusion in dogs. Implication for myocardial salvage. Circulation 1993;87:208–215.PubMedCrossRefGoogle Scholar
  12. 12.
    Kitakaze M., Hori M, Morioka T et al. The infarct size-limiting effect of ischemic preconditioning is blunted by inhibition of 5’-nucleotidase activity and attenuation of adenosine release. Circulation. 1994;89:1237–1246.PubMedCrossRefGoogle Scholar
  13. 13.
    Llyod HGE, Schrader J. The importance of the transmethylation pathway for adenosine metabolism in the hearts. In: Gerlach E, Becker BF (eds) Topics and Perspectives in Adenosine Research. Berlin Heidelberg: Springer-Verlag, 1987:199–207.CrossRefGoogle Scholar
  14. 14.
    Sparks NV, Jr., Bardengeuer H. Regulation of adenosine formation by the heart. Circ. Res. 1986;58:193–201.PubMedCrossRefGoogle Scholar
  15. 15.
    Hori M,. Kitakaze M. Adenosine, the heart, and coronary circulation. Hypertension 1991;18:565–574.PubMedCrossRefGoogle Scholar
  16. 16.
    Kitakaze M., Hori M, Kamada T. Role of adenosine and its interaction with alpha adrenoceptor activity in ischemic and reperfusion injury of the myocardium. Cardiovasc. Res. 1993;27:18–27.PubMedCrossRefGoogle Scholar
  17. 17.
    Imai S, Nakazawa M, Imai M et al. 5’-Nucleotidase inhibitors and the myocardial reactive hyperemia and adenosine content. In:Gerlach E, Becker BF (eds) Topics and Perspectives in Adenosine Research. Berlin Heidelberg: Springer-Verlag,1986:416–424.Google Scholar
  18. 18.
    Kitakaze M., Hori M, Takashima S et al. Superoxide dismutase enhances ischemia-induced reactive hyperemic flow and adenosine release in dogs: A role of 5’-nucleotidase activity. Circ Res 1992;71:558–566.PubMedCrossRefGoogle Scholar
  19. 19.
    Van Wylen DGL. Effects of ischemic preconditioning on interstitial purine metabolite and lactate accumulation during myocardial ischemia Circulation 1994;89:2283–2289.PubMedCrossRefGoogle Scholar
  20. 20.
    Al-Awqati Q. Regulation of ion channels by ABC transporter that secrete ATP. Science 1995;269:805–806.PubMedCrossRefGoogle Scholar
  21. 21.
    Tsuchida A., Liu Y, Liu GS et al. Alphal-adrenergic agonists precondition rabbit ischemic myocardium independent of adenosine by direct activation of protein kinase activation. Circ Res 1994;75:576–585.PubMedCrossRefGoogle Scholar
  22. 22.
    Kitakaze M., Hori M, Morioka T et al. γ1,-Adrenoceptor activation increases ectosolic 5’-nucleotidase activity and adenosine release in rat cardiomyocytes by activing protein kinase C. Circulation 1995;91:2226–2234.PubMedCrossRefGoogle Scholar
  23. 23.
    Kitakaze M., Node K, Minamino T et al. The role of activation of protein kinase C in the infarct size-limiting effect of ischemic preconditioning through activation of ecto-5’-nucleotidase. Circulation 1995;93:781–791.CrossRefGoogle Scholar
  24. 24.
    Kitakaze M., Hori M, Morioka T et al. Alpha1,-adrenoceptor activation mediates the infarct size-limiting effect of ischemic preconditioning through augmentation of 5’-nucleotidase activity. J Clin Invest 1994;93:2197–2205.PubMedCrossRefGoogle Scholar
  25. 25.
    Banerjee A., Locke-Winter C, Rogers KB et al. Preconditioning against myocardial dysfunction after ischemia and reperfusion by α-adrenergic mechanism. Circ Res 1993;73:656–670.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Masafumi Kitakaze
  • Tetsuo Minamino
  • Koichi Node
  • Hiroharu Funaya
  • Masatsugu Hori

There are no affiliations available

Personalised recommendations